Figure 4

Inhibitory effect of cilengitide on tenascin-C-induced proliferation, adhesion, migration, and tube formation in HMVECs. (a) HMVECs were incubated with tenascin-C (300 ng/ml) and cilengitide (10 μM) for 24 h. (b and c) Cell adhesion was assessed by incubating the HMVECs with tenascin-C (300 ng/ml) and cilengitide (10 μM) on fibronectin-coated 96-well plates for 12 h (mean±s.e.m.; n=4 per group). (d) The cell migration was assessed placing HMVECs stimulated with tenascin-C (300 ng/ml) and cilengitide (10 μM) in the upper chamber and allowing the cells to migrate to the other side of the membrane (n=4 per group). (e and f) HMVECs were seeded on BM matrix with tenascin-C (300 ng/ml) and cilengitide (10 μM) (mean±s.e.m.; n=6 per group). Tubes formed by HMVECs were photographed after a 12-h incubation period (4 × objective). (a–f) Cilengitide significantly inhibited tenascin-C-induced proliferation, adhesion, migration, and tube formation of HMVECs. Values are expressed as a percentage relative to the control. *P<0.05, **P<0.01, ANOVA/Dunnett’s test.